Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

Core Viewpoint - Sera Prognostics Inc. has appointed Dr. Tiffany Inglis as Chief Medical Officer to enhance its leadership in women's health diagnostics, particularly focusing on improving maternal and neonatal health through innovative pregnancy biomarker testing [1][2][3]. Company Overview - Sera Prognostics is dedicated to improving the lives of women and babies through precision pregnancy care, aiming to provide early and pivotal pregnancy information to enhance maternal and neonatal health and reduce healthcare delivery costs [4]. Leadership Appointment - Dr. Tiffany Inglis brings extensive clinical leadership experience from Elevance Health and Carelon Health, where she focused on women's and children's health, improving access to quality care while achieving cost savings [2][3]. - Her clinical expertise and experience with major payer networks position her well to lead Sera's clinical operations during a critical phase, including the upcoming publication of the PRIME study and pilot programs with state Medicaid [3][4]. Product Focus - Sera's PreTRM® Test is a blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies, allowing for informed clinical decisions [6][7]. - The test measures proteins in the blood that are highly predictive of preterm birth, enabling identification of at-risk women between 18 and 20 weeks of pregnancy [6][7]. Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is a leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [5]. - The healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [5].